Bicycle Therapeutics plc
BCYC
$9.69
$0.060.62%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.71M | 2.68M | 9.36M | 19.53M | 5.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.71M | 2.68M | 9.36M | 19.53M | 5.33M |
| Cost of Revenue | -60.82M | 45.65M | 38.30M | 32.95M | 51.16M |
| Gross Profit | 68.24M | -42.97M | -28.94M | -13.42M | -45.83M |
| SG&A Expenses | 15.30M | 20.87M | 17.71M | 18.30M | 8.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.37M | 66.52M | 56.01M | 51.25M | 59.57M |
| Operating Income | -67.66M | -63.85M | -46.65M | -31.72M | -54.24M |
| Income Before Tax | -52.94M | -54.25M | -39.70M | -26.91M | -48.78M |
| Income Tax Expenses | -1.08M | -3.45M | 115.00K | -350.00K | 320.00K |
| Earnings from Continuing Operations | -51.85M | -50.80M | -39.81M | -26.56M | -49.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.85M | -50.80M | -39.81M | -26.56M | -49.10M |
| EBIT | -67.66M | -63.85M | -46.65M | -31.72M | -54.24M |
| EBITDA | -65.96M | -61.67M | -45.01M | -30.06M | -52.58M |
| EPS Basic | -0.75 | -0.74 | -0.77 | -0.62 | -1.16 |
| Normalized Basic EPS | -0.52 | -0.48 | -0.48 | -0.40 | -0.72 |
| EPS Diluted | -0.75 | -0.74 | -0.77 | -0.62 | -1.16 |
| Normalized Diluted EPS | -0.52 | -0.48 | -0.48 | -0.40 | -0.72 |
| Average Basic Shares Outstanding | 69.05M | 68.99M | 51.99M | 42.56M | 42.42M |
| Average Diluted Shares Outstanding | 69.05M | 68.99M | 51.99M | 42.56M | 42.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
